THE ANTIBODY-DRUG CONJUGATE LONCASTUXIMAB TESIRINE FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA
Eleonora Calabretta, Mehdi Hamadani, Carmelo Carlo‐Stella
Abstract
Diffuse large B-cell lymphoma (DLBCL) is a heterogenous subtype of non-Hodgkin lymphoma. Relapsed/refractory disease represents remains an unmet medical need, despite the introduction of novel cellular and targeted therapies. Loncastuximab tesirine is a cluster of differentiation19-targeting antibody-drug conjugate approved by the US Food and Drug Administration for relapsed DLBCL after 2 lines of systemic therapy based on a trial showing a 48.3% overall response rate. The spectrum of its clinical applications is expanding and is now being tested in other B-cell malignancies.
Topics & Concepts
Diffuse large B-cell lymphomaAntibody-drug conjugateLymphomaMedicineDrugAntibodyRefractory (planetary science)Clinical trialOncologyCancer researchInternal medicineImmunologyMonoclonal antibodyPharmacologyBiologyAstrobiologyCAR-T cell therapy researchLymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research